Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Mar;61(3):400–403. doi: 10.1038/bjc.1990.87

An immunohistochemical characterisation of the inflammatory cell infiltrate in benign and malignant prostatic disease.

S McClinton 1, I D Miller 1, O Eremin 1
PMCID: PMC1971287  PMID: 1691655

Abstract

The prostate gland is said to be immunologically privileged because it lacks afferent lymphatics and because of the immunosuppressive properties of seminal fluid. To elicit the presence or absence of an immune response within the diseased prostate gland, the infiltrate in prostate glands affected by hyperplasia or adenocarcinoma was phenotypically characterised, using immunohistochemical techniques. An infiltrate, composed mainly of T-lymphocytes (CD-3+), was demonstrated in all glands examined. No difference in the type, level of activation or degree of infiltration was found between those glands affected by hyperplasia (n = 20) and those affected by adenocarcinoma (n = 20). In the malignant cases, there was no correlation between grade (Gleason) or stage (TNM) and the type or degree of mononuclear cell infiltrate. Our findings suggest that the host response, in situ, to hyperplasia and adenocarcinoma is similar and may reflect the fact that the two diseases are often found concurrently in the same gland and in close proximity to one another. The infiltrate, therefore, is unlikely to represent a tumour specific immune response to tumour specific antigens. The significant infiltrate we have demonstrated, and its phenotypic characterisation, would not support the hypothesis that the prostate is immunologically privileged as has been suggested previously.

Full text

PDF
400

Images in this article

401Figure 2
on p.401
401Figure 3
on p.401
402Figure 4
on p.402

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ablin R. J., Bhatti R. A., Bush I. M., Guinan P. D. Immunosuppression of cell- and serum-medicated tumour-associated immunity in prostatic cancer by human seminal plasma. Eur J Cancer. 1980 Jun;16(6):775–780. doi: 10.1016/0014-2964(80)90130-9. [DOI] [PubMed] [Google Scholar]
  2. Catalona W. J. Immunobiology of carcinoma of the prostate. Invest Urol. 1980 Mar;17(5):373–377. [PubMed] [Google Scholar]
  3. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  4. Evans R. Macrophage requirement for growth of a murine fibrosarcoma. Br J Cancer. 1978 Jun;37(6):1086–1089. doi: 10.1038/bjc.1978.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gittes R. F., McCullough D. L. Occult carcinoma of the prostate: an oversight of immune surveillance--a working hypothesis. J Urol. 1974 Aug;112(2):241–244. doi: 10.1016/s0022-5347(17)59697-4. [DOI] [PubMed] [Google Scholar]
  6. Gleason D. F. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966 Mar;50(3):125–128. [PubMed] [Google Scholar]
  7. Greene W. C., Leonard W. J. The human interleukin-2 receptor. Annu Rev Immunol. 1986;4:69–95. doi: 10.1146/annurev.iy.04.040186.000441. [DOI] [PubMed] [Google Scholar]
  8. Halpert B., Schmalhorst W. R. Carcinoma of the prostate in patients 70 to 79 years old. Cancer. 1966 May;19(5):695–698. doi: 10.1002/1097-0142(196605)19:5<695::aid-cncr2820190515>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  9. Ioachim H. L. The stromal reaction of tumors: an expression of immune surveillance. J Natl Cancer Inst. 1976 Sep;57(3):465–475. doi: 10.1093/jnci/57.3.465. [DOI] [PubMed] [Google Scholar]
  10. Kabawat S. E., Bast R. C., Jr, Welch W. R., Knapp R. C., Bhan A. K. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer. 1983 Nov 15;32(5):547–554. doi: 10.1002/ijc.2910320505. [DOI] [PubMed] [Google Scholar]
  11. Kernohan N. M., Sewell H. F. Interleukin-2 receptor expression in benign and malignant melanocytic skin lesions. J Pathol. 1989 Apr;157(4):315–319. doi: 10.1002/path.1711570408. [DOI] [PubMed] [Google Scholar]
  12. McNeal J. E. Origin and development of carcinoma in the prostate. Cancer. 1969 Jan;23(1):24–34. doi: 10.1002/1097-0142(196901)23:1<24::aid-cncr2820230103>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  13. Mostofi F. K., Sesterhenn I. Plenary lecture: lymphocytic infiltration in relationship to urologic tumors. Natl Cancer Inst Monogr. 1978 Dec;(49):133–141. [PubMed] [Google Scholar]
  14. Ponder B. A., Wilkinson M. M. Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry. J Histochem Cytochem. 1981 Aug;29(8):981–984. doi: 10.1177/29.8.7024402. [DOI] [PubMed] [Google Scholar]
  15. Quayle A. J., Szymaniec S., Hargreave T. B., James K. Studies on the immunosuppressive effect of seminal plasma. Br J Urol. 1987 Dec;60(6):578–582. doi: 10.1111/j.1464-410x.1987.tb05045.x. [DOI] [PubMed] [Google Scholar]
  16. Steele R. J., Eremin O., Brown M., Hawkins R. A. A high macrophage content in human breast cancer is not associated with favourable prognostic factors. Br J Surg. 1984 Jun;71(6):456–458. doi: 10.1002/bjs.1800710618. [DOI] [PubMed] [Google Scholar]
  17. Targan S. R., Kagnoff M. F., Brogan M. D., Shanahan F. Immunologic mechanisms in intestinal diseases. Ann Intern Med. 1987 Jun;106(6):853–870. doi: 10.7326/0003-4819-106-6-853. [DOI] [PubMed] [Google Scholar]
  18. Underwood J. C. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer. 1974 Dec;30(6):538–548. doi: 10.1038/bjc.1974.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Vose B. M., Moore M. Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol. 1985 Jan;22(1):27–40. [PubMed] [Google Scholar]
  20. Waldmann T. A. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science. 1986 May 9;232(4751):727–732. doi: 10.1126/science.3008337. [DOI] [PubMed] [Google Scholar]
  21. el-Demiry M. I., Hargreave T. B., Busuttil A., James K., Ritchie A. W., Chisholm G. D. Lymphocyte sub-populations in the male genital tract. Br J Urol. 1985 Dec;57(6):769–774. doi: 10.1111/j.1464-410x.1985.tb07051.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES